Immunovant, Inc.
$28.53
▼
-2.39%
2026-04-21 07:30:00
immunovant.com
NMS: IMVT
Explore Immunovant, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.81 B
Current Price
$28.53
52W High / Low
$29.48 / $13.36
Stock P/E
—
Book Value
$4.85
Dividend Yield
—
ROCE
-61.93%
ROE
-69.35%
Face Value
—
EPS
$-2.67
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
362
Beta
0.67
Debt / Equity
0
Current Ratio
15.74
Quick Ratio
11.16
Forward P/E
-9.34
Price / Sales
—
Enterprise Value
$3.99 B
EV / EBITDA
-8.2
EV / Revenue
—
Rating
Buy
Target Price
$40.12
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Actinium Pharmaceuticals, Inc. | $1.44 | — | $42.98 M | — | -82.74% | -1.67% | $1.95 / $0.95 | $0.25 |
| 2. | VYNE Therapeutics Inc. | $0.63 | — | $20.33 M | — | -107.15% | -66.96% | $1.99 / $0.28 | $0.83 |
| 3. | Xenetic Biosciences, Inc. | $3.4 | — | $7.09 M | — | -38.33% | -40% | $13.93 / $1.9 | $3.23 |
| 4. | Oruka Therapeutics, Inc. | $68.87 | — | $3.48 B | — | -25.79% | -24.69% | $70.5 / $8.36 | $9.63 |
| 5. | Janux Therapeutics, Inc. | $15.87 | — | $962.36 M | — | -16.15% | -11.48% | $35.34 / $12.12 | $15.85 |
| 6. | Erasca, Inc. | $21.71 | — | $5.91 B | — | -35.74% | -33.27% | $19.78 / $1.06 | $1.14 |
| 7. | Orchestra BioMed Holdings, Inc. | $4.35 | — | $268.03 M | — | -52.8% | -1.09% | $5.42 / $2.2 | $0.94 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -114.36 M | -131.76 M | -127.22 M | -113.83 M | -114.3 M | — |
| Net Profit | -110.64 M | -126.5 M | -120.61 M | -106.45 M | -111.12 M | — |
| EPS in Rs | -0.54 | -0.62 | -0.59 | -0.52 | -0.55 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -438.15 M | -270.21 M | -208.28 M | -156.03 M |
| Net Profit | -413.84 M | -259.34 M | -210.96 M | -156.73 M |
| EPS in Rs | -2.03 | -1.27 | -1.04 | -0.77 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 776.22 M | 666.37 M | 405.84 M | 515.56 M |
| Total Liabilities | 68.78 M | 48.61 M | 43.34 M | 45.74 M |
| Equity | 707.45 M | 617.76 M | 362.49 M | 469.82 M |
| Current Assets | 767.66 M | 665.77 M | 404.33 M | 512.93 M |
| Current Liabilities | 68.78 M | 48.61 M | 43.3 M | 44.52 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -375.87 M | -214.23 M | -188.19 M | -106.11 M |
| Investing CF | -0.76 M | -0.36 M | -0.2 M | -0.25 M |
| Financing CF | 454.49 M | 472.43 M | 70.89 M | 200.13 M |
| Free CF | -376.63 M | -214.59 M | -188.39 M | -106.37 M |
| Capex | -0.76 M | -0.36 M | -0.2 M | -0.25 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -59.58% | -22.93% | -34.6% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.